Acuity Brands (AYI) remains a buy as software-led revenue surges and FCF strengthens. Read here for a detailed investment ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback